Lorigerlimab Hits 25% Response Rate in Clear Cell Gynecologic Cancer Interim Phase 2 Data
MGNX sits 75% above its 52-week low of $1.29 on elevated volume (6.7× avg).
Summary
Interim Phase 2 LINNET data for lorigerlimab, a PD-1/CTLA-4 bispecific, showed a 25% confirmed objective response rate (4/16) and 44% disease control rate in clear cell gynecologic cancers, with all responses still ongoing at the September 1 cutoff. Median progression-free survival in the 17 safety-evaluable CCGC patients was 2.9 months and the 6-month PFS rate was 33%. Safety was manageable but not clean: Grade ≥3 treatment-related adverse events hit 49% of the 41 patients, and 24% discontinued treatment, including one Grade 5 event in the platinum-resistant ovarian cohort. MacroGenics is now enrolling 20 more CCGC patients at a lower 3 mg/kg dose and expects updated results in the first half of 2027. This is the second positive clinical readout in four days after the October 23 MGC026 Phase 1 data, and it matters because the company is a micro-cap whose thesis rests on pipeline data rather than revenue.
At the time of this announcement, MGNX was trading at $2.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $143.3M. The 52-week trading range was $1.29 to $5.08. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.